Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China-Reference-Cited by-同舟云学术

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

Published:2019-01 Issue: Volume:78 Page:44-49
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Fan Qianqian,Ming Wai-kit,Yip Wai-ying,You Joyce H.S.^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference35 articles.

1. Women and men in Hong Kong key statistics 2017 Edition;Census and Statistics Department, Hong Kong SAR,2017

2. National income;Census and Statistics Department, Hong Kong SAR,2018

3. Tuberculosis manual;Centre for Health Protection, Department of Health,2006

4. Guideline on the management of multi-drug resistant and extensively drug resistance tuberculosis in Hong Kong;Chan,2008

5. Early unplanned readmission of patients with newly diagnosed tuberculosis discharged from acute hospital to ambulatory treatment;Chu;Respirology,2001

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses;PharmacoEconomics;2024-08-07

2. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis;Frontiers in Public Health;2024-04-16

3. Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting;The International Journal of Tuberculosis and Lung Disease;2024-02-01

4. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

5. Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China;BIOMED ENVIRON SCI;2023